Sugen Incorporated

Exelixis, Inc.

Genentech, Inc.

Bristol-myers Squibb Compnay

Oncogen

Other

Eli Lilly and Company

Immunogen, Inc.

Zymeworks Inc.

Imclone LLC

F. Hoffmann-la Roche Ag

Zymeworks Bc Inc.

Gregory D Plowman

Lori Friedman

Yan Wu

Mohammed Shoyab

Weilan Ye

Helen Louise Francis-Lang

Marcia Belvin

Wei-Ching Liang

Roel P Funke

Kevin Mossie

Ingegerd E Hellstrom

Karl E Hellstrom

Bahija Jallal

Danxi Li

Joseph Schlessinger

Joseph P Brown

Anthony F Purchio

Timothy S Heuer

Dale Lincoln Ludwig

Timothy M Rose

Sima Lev

David Whyte

Shiu-Lok Hu

Anan Chuntharapai

Michael R Costa

Jeffrey Scott Larson

Clay B Siegall

David K Bol

Felix D Karim

Yang Shen

Matthew V Lorenzi

Lynn Margaret Bjerke

Igor Edmondo Paolo D'Angelo

Yiwen Li

Douglas O Clary

Robert D Mass

Charles D Estin

Danix Li

Ricardo Martinez

Sridhar Pennathur

Vicki Lynn McDonald

Candace Swimmer

Michael Dewain Kalos

Hans K Erickson

Stephanie A Robertson

Elior Peles

Marc Tessier-Lavigne

Sara A Courtneidge

Mario N Lioubin

Torsten Bernhard Trowe

Paul J Balderes

Stefan Schulte-Merker

Christopher M Moxham

Ulrike Eisenmann

Gordon Mark Stott

Alan C Rigby

Andreas Michael Vogel

James G Bradley

James Garrett Bradley

Jochen Konrad Scheel

Jean-Michel Culouscou

Torsten Tilmann Will

Yinsheng Jin

Tak Hung

James Bishoff

Rolf Peter Ryseck

Lata Jayaraman

James Bischof

Peter Flanagan

Joerg Heinrich Odenthal

Susan Onrust

David Markby

Hinrich Alexander Habeck

Scott W Eastman

Thomas I Koblizek

Keith E Joho

Igor Edmondo D'angelo

Helen Francis-Lang

The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

Checkpoint inhibitor bispecific antibodies

The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.

Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment

The present invention relates to the use of VEGF antagonists and a novel anti-&#x3b1;5&#x3b2;1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-&#x3b1;5&#x3b2;1 antibodies and methods of making and using them.

Antibodies

The present invention provides new anti-&#x3b1;5&#x3b2;1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies.

Anti-&#x3b1;5&#x3b2;1 antibodies and uses thereof

Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.

SCDs as modifiers of the p53 pathway and methods of use

The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.

Anti-alpha5/beta1 antibody

Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.

MAP3Ks as modifiers of the p53 pathway and methods of use

Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.

Marks as modifiers of the p53 pathway and methods of use

Anti- &#x3b1;5 &#x3b2;1 antibodies and uses thereof

Human MYLK genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MYLK are provided.

Mylks as modifiers of branching morphogenesis and methods of use

Human hPRP4 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of hPRP4 are provided.

HPRP4s modifiers of the p53 pathway and methods of use

The present invention relates to the use of VEGF antagonists and a novel anti-&#x3b1;5&#x3b2;1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-&#x3b1;5&#x3b2;1 antibodies and methods of making and using them.

The present invention relates to AUR1 and/or AUR2 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for AUR1 and/or AUR2 related diseases or conditions characterized by an abnormal interaction between a AUR1 and/or AUR2 polypeptide and a AUR1 and/or AUR2 binding partner.

Diagnosis and treatment of AUR1 and/or AUR2 related disorders

The present invention relates to PTP05 polypeptides and PTP10 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for PTP05 and/or PTP10 related diseases or conditions characterized by an abnormal interaction between a PTP05 polypeptide and a PTP05 binding partner and/or a PTP10 polypeptide and a PTP10 binding partner.

Diagnosis and treatment of PTP related disorders

Growing community of inventors

San Carlos, CA, United States of America

Gregory D Plowman